tbuckley/cabot-search huggingface dataset:
Human seminal plasma allergy as a cause of postcoital asthma
Authors: A Shah, MK Agarwal
Journal: European Respiratory Journal (1988)

CD4 Th cells are organizers of the immune response, directing other immune cells to initiate and maintain effective humoral and cellular immunity. CD4 T cells differentiate into distinct Th effector or regulatory subsets in response to signals delivered to them during the course of infection. Ikaros is a transcription factor that is expressed in blood cells from the level of the hematopoietic stem cell. It is required for normal thymic T cell development and serves as a tumor suppressor, as lack of Ikaros in developing lymphoid cells results in leukemia. To study the role of Ikaros in CD4 T cell differentiation and function, an Ikaros conditional knockout mouse was developed such that Ikaros expression was deleted specifically in mature T cells, thus avoiding defects observed in germline Ikaros mutant mice. Using this model system, we have shown that in the absence of Ikaros, CD4 T cells are able to attain Th1, Th2, and Th17, but not inducible regulatory T, cell fates. However, they show enhanced expression of a cohort of proinflammatory cytokines, resulting in differentiation of Th17 cells with a phenotype that has been associated with autoimmunity and pathological inflammation. In addition, we define Ikaros as a repressor of the gene program associated with the response to type I IFNs, another key pathway whose deregulation is linked to autoimmunity. Taken together, these data definitively define Ikaros as a critical regulator at the center of the inflammatory response in T cells and highlight a potential role in suppressing autoimmunity.
The Link Between Sauna Bathing and Mortality May Be Noncausal
Authors: Yoram Epstein, Yehuda Shoenfeld
Journal: JAMA Internal Medicine (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Post-Transplant Cyclophosphamide Following a Myeloablative Conditioning For Hematologic Malignancies Receiving An Unmanipulated Haploidentical Bone Marrow Transplant
Authors: Anna Maria Raiola, Anna Ghiso, Alida Dominietto, Carmen Di Grazia, Francesca Gualandi, Riccardo Varaldo, Federica Galaverna, Maria Teresa Van Lint, Teresa Lamparelli, Stefania Bregante, Maurizio Miglino, Filippo Ballerini, Andrea Bacigalupo
Journal: Blood (2013)
A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL)
Authors: F. J. Giles, R. Larson, P. Le Coutre, M. Baccarani, R. Tavorath, L. Alland, H. M. Kantarjian, T. Hughes, O. Ottmann
Journal: Journal of Clinical Oncology (2006)

6536 Background: AMN107 is a highly selective, aminopyrimidine which is 30-fold more potent in vitro than imatinib and active against 32/33 imatinib resistant Bcr-Abl mutations. Methods: This open-label study evaluated safety and efficacy of AMN107 (400 mg bid) by hematologic/cytogenetic response (HR/CyR) rates in imatinib resistant/ intolerant BC or relapsed/refractory ALL pts. Results: Preliminary data from this ongoing study are presented for 18 BC and 6 ALL (5 relapsed/refractory, 1 minimal residual disease) pts. Baseline mutation data are available for 6 BC and 2 ALL pts: 2 and 1, respectively, had Bcr-Abl mutations. The overall median age was 54 yrs and the overall median exposure was 84 days. Seven patients remain on treatment (5 BC, 2 ALL) and 17 discontinued (3 adverse events, 9 progressive disease (PD), 3 deaths, 2 other). Two BC pts died of PD. 1 ALL pt had sudden cardiac death. HR was reported in 7 (38%) BC pts; 5 complete HR and 2 marrow responses/no evidence of leukemia. 3 BC pts had CyR (2 complete, 1 minor). Complete remission was reported in 2 (33%) ALL (1 relapsed/refractory and 1 MRD) pts. Adverse events in ≥ 10% were rash in 9 (37%) pts, thrombocytopenia in 8 (33%) pts (Gr 3/4 in 7 (29%), nausea in 7 (29%) pts, pyrexia in 7 (29%) pts (Gr 3/4 in 2 (8%)); vomiting in 7 (29%) pts (Gr 3/4 in 1 (4%), diarrhea, fatigue in 6 (25%) pts each, headache in 6 (25%) pts (Gr 3/4 in 1 (4%)), neutropenia in 6 (25%) pts (all Gr 3/4), anemia in 5 (21%) pts (Gr 3/4 in 4 (17%)), pain in extremity in 5 (21%) pts (Gr 3/4 in 1 (4%)), pain, peripheral edema in 4 (17%) pts each, pruritus in 4 (17%) pts (Gr 3/4 in 1 (4%)), leukocytosis in 3 (13%) pts (Gr 3/4 in 1 (4%)), arthralgia, pharyngolaryngeal pain, and upper abdominal pain 3 (13%) each. Conclusions: AMN107 has clinical activity and an acceptable safety and tolerability profile in pts with imatinib-resistant or intolerant BC and relapsed/refractory Ph+ ALL pts [Table: see text]
Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
Authors: C Steele, B Rovner, G A Chase, M Folstein
Journal: American Journal of Psychiatry (1990)

Two hundred ten community-dwelling patients with Alzheimer's disease were examined prospectively by psychiatrists as part of a longitudinal study. Twenty-five of these patients who were institutionalized during the next 3 years were then matched to 25 patients who were not institutionalized, and the groups were compared. The patients who had been institutionalized had higher scores on standardized psychiatric rating scales but not on formal neuropsychological tests of cognition. These results suggest that potentially treatable (noncognitive) behavioral and psychiatric symptoms are risk factors for institutionalization, and that treating these symptoms might delay or prevent institutionalization of some patients.
Familial cases of idiopathic pulmonary fibrosis: Clinical observation
Authors: Lubov Novikova, Yulia Ilkovich, Michail Ilkovich
Journal: European Respiratory Journal (2011)

Background:  Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, often fatal interstitial lung disease of unknown etiology. Familial idiopathic pulmonary fibrosis (FIPF) is defined when two or more affected individuals are identified in one family. FIPF accounts for 0.5-2.2% of all IPF cases.   Results:  We found 10 FIPF patients in 5 families among totally observed 475 IPF cases. There were 3 pairs of siblings (2 males and 4 females) and 2 pairs of mother and daughter. FIPF was diagnosed according to ATS/ERS criteria, histologically proven in 9 of 10 subjects. The mean age of IPF manifestation appears to be low: 37±5.3 years. All patients were treated by systemic corticosteroids, 4 of 10 - in combination with cytotoxic agents. 2 of 10 (mother and daughter in one family) have rather favorable course of IPF and are alive. The rest 8 cases had rapid severe progression of disease. Among them two patients are still alive, but demonstrate severe deterioration of their conditions, 6 - died within five years since first symptoms of disease occurred. The cause of death was progressive respiratory failure in 4 cases, respiratory failure with pneumonia in one case and lung cancer in another case.   Conclusion:  2.1% of our cohort of IPF patients has familial history of pulmonary fibrosis. Although rare, such cases represent an important subgroup in which genetic susceptibility to lung fibrosis plays a significant role. FIPF appears histologically indistinguishable from non-familial forms, but characterized by younger age of onset, resistance to treatment, progressive course and unfavorable prognosis. Molecular genetic analysis could improve our understanding of the pathogenic mechanisms of IPF.
Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil
Authors: S.S. Gonçalves, C.S. Amorim, M. Nucci, A.C.B. Padovan, M.R.S. Briones, A.S.A. Melo, A.L. Colombo
Journal: Clinical Microbiology and Infection (2009)
The role of food allergy in adult onset asthma
Authors: M. Amelink, S.B. de Nijs, P. van Spiegel, F.H. Krouwels, E.J.M. Weersink, A. ten Brinke, P.J. Sterk, E.H. Bel
Journal: European Respiratory Journal (2011)

Background: Adult onset asthma is a poorly characterized phenotype of asthma. Whereas in childhood-onset asthma food allergies are closely related to the development of asthma (Zeiger JACI 1995), this relationship has never been studied in adult onset asthma. We hypothesize that food allergies are present in adult onset asthma, in particular in patients with high levels of total IgE.

Aim: To investigate the presence of specific IgE antibodies against a panel of common food and aeroallergens in patients with adult onset asthma, and to relate this to clinical, lung function and inflammatory markers.

Methods: In 150 patients (65% female; age 52.3 (±13.5)yr) specific IgE against food allergens (milk, soy, cod, peanut, ovalbumin, wheat), aeroallergens (house dust mite, cat, dog, tree, grass, herbs, mould), total IgE, FeNO and spirometry were cross-sectionally compared between patients with and without (food) allergies.

Results: 

View this table:



Conclusions: 10% of patients with adult onset asthma have food allergies. These patients have higher levels of total IgE and are more often males. This implies that screening for food allergies in patients with adult onset asthma and high levels of IgE is warranted.
Fibromyalgia and major affective disorder: a controlled phenomenology and family history study
Authors: J I Hudson, M S Hudson, L F Pliner, D L Goldenberg, H G Pope
Journal: American Journal of Psychiatry (1985)

Fibromyalgia is a form of nonarticular rheumatism characterized by diffuse musculoskeletal pain. To investigate the relationship between fibromyalgia and major affective disorder, the authors evaluated 31 patients with fibromyalgia and 14 patients with rheumatoid arthritis for rates of current or past major affective disorder and family history of major affective disorder. Both the rate of major affective disorder and the familial prevalence of major affective disorder were significantly higher in the fibromyalgia patients than the rheumatoid arthritis patients. The results suggest that fibromyalgia may be related to major affective disorder.
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
Authors: Cornelia L Trimble, Matthew P Morrow, Kimberly A Kraynyak, Xuefei Shen, Michael Dallas, Jian Yan, Lance Edwards, R Lamar Parker, Lynette Denny, Mary Giffear, Ami Shah Brown, Kathleen Marcozzi-Pierce, Divya Shah, Anna M Slager, Albert J Sylvester, Amir Khan, Kate E Broderick, Robert J Juba, Timothy A Herring, Jean Boyer, Jessica Lee, Niranjan Y Sardesai, David B Weiner, Mark L Bagarazzi
Journal: The Lancet (2015)
This World: Bad Medicine
Authors: Peter Winstanley
Journal: BMJ (2005)

BBC 2, Tuesday 12 July at 9 pm Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img> T his piece of investigative journalism covered the massive worldwide trade in substandard drugs and the harm that these do. Nigeria was the focus, but I suspect that the programme could have been made about almost any developing country. The context in which this scam flourishes is one of, firstly, widespread failure to contain major killers, most notably infectious diseases such as malaria, tuberculosis, and HIV; secondly, personal and national poverty; and thirdly, underdeveloped regulatory systems. Malaria and tuberculosis are both curable, and HIV can be contained by drugs, and people the world over have the right to expect standards of quality, efficacy, and safety. Tablets must contain the specified mass of the active ingredient, must not contain more than (defined) traces of contaminants, and must be bioavailable. Furthermore, the efficacy and safety of a drug must have been shown as part of rigorous clinical trials before the drug is launched. Legislation around these basic principles has evolved over the centuries but has most recently been … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif
Alpha<sub>1</sub>-Antitrypsin Deficiency
Authors: Edwin K. Silverman, Robert A. Sandhaus
Journal: New England Journal of Medicine (2009)

A 60-year-old white man presents for evaluation of progressive dyspnea. He is a former smoker with a 20-pack-year smoking history and a 10-year history of chronic obstructive pulmonary disease (COPD). There is no family history of COPD. Severe airflow obstruction is seen on spirometry, with a forced expiratory volume in 1 second that is 40% of the predicted value. Should he be evaluated for alpha1-antitrypsin (AAT) deficiency? If AAT deficiency is documented, how should his case be managed?
Late lung metastasis of endometrial cancer. Two rare cases of patients with late lung metastasis of primary endometrial cancer 14 and 17 years after initial treatment
Authors: Roger Fei Falkenstern-Ge, Markus Wohlleber, Martin Kimmich, Sabine Bode-Erdmann, German Ott, Martin Kohlhäufl
Journal: European Respiratory Journal (2012)

Introduction   The longest interval of lung metastasis from endometrial cancer was initially reported 17 years after standard surgical treatment.   Aims and objectives   Nearly 80% of all recurrences of endometrial cancer occur within 3 years after the initial treatment. We report two cases of lung metastasis 14 and 17 years after the initial surgical treatment of endometrial cancer.   Methods   A 71- year-old female was referred to our center for histological diagnosis of lung lesions. Histological biopsy showed lung metastasis of an endometrial cancer which was resected 17 years ago.  A 77- year-old female was also referred for histological diagnosis of multiple lung lesions and a clavicle metastasis. Both clavicle and lung biopsy revealed metastasis of an endometrial cancer treated 14 years ago surgically.   Results   Our first patient was treated with organ- preserving metastatic wedge resection. The latency period in the first case between initial treatment of endometrial cancer and pulmonary metastases was 17 years. Our second patient with widespread metastasis was treated with palliative radiotherapy and systemic chemotherapy. The latency period between initial diagnosis and treatment of endometrial cancer and pulmonary metastases in the second case was 14 years.   Conclusion   Lung metastases originating from tumors of the female genital tract are very rare. We report of lung metastasis from endometrial cancer with a latency period of 14 and 17 years. To our knowledge, in the literature there is only one case reported with a similar extreme latency.
From the FDA, we still hear mostly thunderous silence
Authors: Erick H Turner
Journal: BMJ (2015)

Lurie and colleagues’ comparison of FDA letters not approving applications for new drugs and associated public announcements from sponsors provides a valuable but rare peek behind the Food and Drug Administration’s “iron curtain.” The discussion section begins, “our analysis found that the FDA’s reasons for not approving marketing applications for new molecular entities are not being fully conveyed to the public.”1 On the basis of the …
The relation of six-minute walk test and lung function in interstitial lung disease
Authors: Raquel Rosa, Ana Sofia Santos, Ricardo Coelho, Dionísio Maia, Alexandra Borba, Inês Gonçalves, João Cardoso
Journal: European Respiratory Journal (2013)

Introduction: The six-minute walk test (6MWT) is widely used in evaluating patients with interstitial lung diseases (ILD). However studies relating 6MWT and pulmonary function tests (PFT) of these patients are scarce.

Aim: To evaluate the relation between walk distance (6MWTD), oxygen desaturation (ΔSO2) and breathlessness perception during 6MWT and PFT in ILD patients.

Methods: Seventy ILD patients were included (mostly idiopathic pulmonary fibrosis). Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), total lung capacity (TLC), diffusion capacity for carbon monoxide (DLCO) and carbon monoxide transfer coefficient (KCO) were measured and expressed as percent predicted. A 6MWT was performed in accordance with international recommendations. The 6MWTD, ΔSO2 and Borg Dyspnea Index (BDI) were recorded. Means with standard deviations were calculated for the PFT and 6MWT indices. Pearson’s correlation coefficient was applied. Values of p<0.05 were considered significant.

Results: The mean 6MWTD was 448 meters (±90). Mean baseline oxygen saturation was 96% and mean ΔSO2 was 7.7% (±6.3). We found a correlation between the 6MWTD and DLCO (r=0.24; p=0.04) and between ΔSO2 and FVC, FEV1, TLC, DLCO and KCO (r=-0.47, -0.46, -0.45, -0.59, -0.44, respectively; p=0.00). A correlation was evident between post 6MWT BDI and DLCO (r=-0.25; p=0.04) and KCO (r=-0.32; p=0.01).

Conclusion: We found a stronger correlation between ΔSO2 and DLCO. The other correlations found were also significant and support the 6MWT as a tool for the functional and clinical assessment of ILD patients.
Cancer survival in Britain
Authors: P G de Takats, N. Summerton, M. Sant, F. Berrino, J. W. W Coebergh, I. Kunkler, A. Rodger, K. Taylor
Journal: BMJ (1999)

# Cancer chemotherapy costs money {#article-title-2} EDITOR—I strongly endorse Sikora's claim that poor rates of survival from cancer in the United Kingdom reflect a lack of NHS resources.1 Increasing the number of specialist oncologists will not, however, make up for the massive shortfall in funds required to provide these oncologists with the essential tools of their trade. Recent review of the budgetary allocation to Addenbrooke's Oncology Centre identified that, on average, £1700 a year is available to spend on drugs for any individual patient with cancer. Since a single course of chemotherapy may cost between £50 and £1500, oncologists cannot be expected to deliver the quality of care the public expects to receive. There are no other untapped sources of funding. Our clinical practice is already heavily subsidised: about one in six of all new patients with cancer referred to Addenbrooke's receives his or her standard chemotherapy courtesy of funds raised from industry sponsored research. The government cannot claim commitment to improving cancer care while patients are being denied effective treatments on the grounds of lack of affordability. 1. 1.↵1. Sikora K . Cancer survival in Britain. BMJ 1999; 319: 461–462. [OpenUrl][1][FREE Full Text][2] # Diagnosis in primary care is important factor {#article-title-4} EDITOR—Sikora paints a bleak picture of the quality of cancer care in Britain compared with France, Germany, and Sweden.1 I agree with most of his editorial but take issue with his dismissal of diagnostic delay in primary care as being an important factor. The fact that patients reach secondary care at similar stagings throughout Europe should not allow complacency. Primary care diagnostic oncology in Britain may simply be as bad as that in the rest of Europe. The Medical Defence Union has reported that failure and delay in … [1]: {openurl}?query=rft.jtitle%253DBMJ%26rft.stitle%253DBMJ%26rft.issn%253D0007-1447%26rft.aulast%253DSikora%26rft.auinit1%253DK.%26rft.volume%253D319%26rft.issue%253D7208%26rft.spage%253D461%26rft.epage%253D462%26rft.atitle%253DCancer%2Bsurvival%2Bin%2BBritain%26rft_id%253Dinfo%253Apmid%252F10454383%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/ijlink?linkType=FULL&journalCode=bmj&resid=319/7208/461&atom=%2Fbmj%2F319%2F7224%2F1572.atom
Gene Expression for Dihydropyrimidine Dehydrogenase and Thymidine Phosphorylase Influences Outcome in Epithelial Ovarian Cancer
Authors: Ritsuto Fujiwaki, Kohkichi Hata, Kentaro Nakayama, Manabu Fukumoto, Kohji Miyazaki
Journal: Journal of Clinical Oncology (2000)

Dihydropyrimidine dehydrogenase (DPD) is a pyrimidine salvage enzyme responsible for degradation of thymine, which is produced from thymidine by thymidine phosphorylase (TP). Our purpose was to determine whether DPD affects prognosis in patients with epithelial ovarian cancer and how the two enzymes may interact in such effects.DPD gene expression was analyzed by reverse transcription-polymerase chain reaction in 27 samples from normal ovaries and the 85 epithelial ovarian cancers previously studied with regard to TP gene expression.DPD gene expression was significantly lower in epithelial ovarian cancers than in normal ovaries (P: <.0001), whereas TP gene expression and the ratio of TP to DPD gene expression (TP:DPD) were significantly higher in epithelial ovarian cancer (P: <.0001 for both). In patients with epithelial ovarian cancer, DPD gene expression and the TP:DPD ratio did not significantly correlate with any clinicopathologic factors. Patients with a high TP:DPD ratio (higher than the median) had significantly poorer outcomes than those with lower ratios (P: =.0002). The difference in survival between groups with high and low TP:DPD ratios was greater than the difference between groups with high and low TP gene expression. Multivariate analysis showed the TP:DPD ratio to be the independent prognostic factor (P: =.0002). In tumors with high TP gene expression, low DPD gene expression significantly correlated with poor survival (P: =. 04).Downregulation of DPD gene expression may enhance the negative prognostic effect of high TP gene expression in patients with epithelial ovarian cancer. Certain newly available chemotherapeutic choices may take the TP:DPD ratio into consideration.